Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.

Claudia Ibarra Biography and Net Worth

COO of DermTech

Claudia Ibarra has over 25 years of experience in clinical laboratory operations, in the areas of oncology, immunology and molecular biology. In her leadership roles, she grew and developed the laboratory operations of renowned diagnostic companies to a highly efficient and successful state, with unparalleled quality, service level and inspection track records. Before joining DermTech, Mrs. Ibarra served as Senior Vice President, Laboratory Operations at Exagen, Director of the molecular oncology laboratory at Genoptix, Inc., where she was also the Molecular Genetic Training Program Coordinator, and other reference clinical laboratories focused on immunology and solid tumors. Mrs. Ibarra holds a degree in Biochemistry with specialization in clinical laboratory science from the University of Buenos Aires, Argentina and a California License as Clinical Laboratory Scientist.

What is Claudia Ibarra's net worth?: The estimated net worth of Claudia Ibarra is at least $0.00 as of December 11th, 2023. Ms. Ibarra owns 193,547 shares of DermTech stock worth more than $0 as of November 5th. This net worth evaluation does not reflect any other investments that Ms. Ibarra may own. Learn More about Claudia Ibarra's net worth.
How do I contact Claudia Ibarra?: The corporate mailing address for Ms. Ibarra and other DermTech executives is 11099 N. Torrey Pines Road Suite 100, La Jolla CA, 92037. DermTech can also be reached via phone at (858) 450-4222 and via email at [email protected]. Learn More on Claudia Ibarra's contact information.
Has Claudia Ibarra been buying or selling shares of DermTech?: Claudia Ibarra has not been actively trading shares of DermTech during the past quarter. Most recently, Claudia Ibarra sold 331 shares of the business's stock in a transaction on Monday, December 11th. The shares were sold at an average price of $1.45, for a transaction totalling $479.95. Following the completion of the sale, the chief operating officer now directly owns 193,547 shares of the company's stock, valued at $280,643.15. Learn More on Claudia Ibarra's trading history.
Who are DermTech's active insiders?: DermTech's insider roster includes John Dobak (CEO), Claudia Ibarra (COO), Scott Pancoast (Director), Enrico Picozza (Director), Kevin Sun (CFO), and Todd Wood (Insider). Learn More on DermTech's active insiders.
Are insiders buying or selling shares of DermTech?: In the last year, insiders at the sold shares 5 times. They sold a total of 13,436 shares worth more than $20,494.84. The most recent insider tranaction occured on December, 11th when CFO Kevin M Sun sold 447 shares worth more than $648.15. Insiders at DermTech own 5.1% of the company. Learn More about insider trades at DermTech.
Information on this page was last updated on 12/11/2023.

Claudia Ibarra Insider Trading History at DermTech

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/11/2023	Sell	331	$1.45	$479.95	193,547
12/7/2023	Sell	3,911	$1.53	$5,983.83	196,485
9/11/2023	Sell	322	$1.89	$608.58	200,396
9/8/2023	Sell	7,378	$1.93	$14,239.54	200,718
6/12/2023	Sell	322	$2.85	$917.70	208,096
6/7/2023	Sell	3,916	$2.53	$9,907.48	210,789
3/13/2023	Sell	378	$3.26	$1,232.28	214,705
3/7/2023	Sell	7,091	$4.06	$28,789.46	150,731
12/12/2022	Sell	328	$2.22	$728.16	157,822
12/8/2022	Sell	2,496	$2.32	$5,790.72	158,150
12/6/2022	Sell	137	$2.44	$334.28	160,646
9/12/2022	Sell	322	$5.99	$1,928.78	160,783
9/8/2022	Sell	2,449	$5.65	$13,836.85	161,105
9/6/2022	Sell	133	$5.43	$722.19	163,554
6/13/2022	Sell	345	$4.81	$1,659.45	163,682
6/8/2022	Sell	2,439	$6.26	$15,268.14	164,027
6/6/2022	Sell	133	$6.48	$861.84	166,466
3/11/2022	Sell	320	$14.55	$4,656.00
3/7/2022	Sell	623	$13.03	$8,117.69
12/13/2021	Sell	473	$16.71	$7,903.83
12/8/2021	Sell	3,450	$18.46	$63,687.00
9/13/2021	Sell	457	$36.19	$16,538.83
9/8/2021	Sell	3,020	$36.18	$109,263.60
6/8/2021	Sell	2,405	$43.43	$104,449.15	118,510
3/8/2021	Sell	2,431	$50.04	$121,647.24
12/8/2020	Sell	2,421	$11.86	$28,713.06	115,246
9/10/2020	Sell	7,605	$10.82	$82,286.10	120,470

Claudia Ibarra Buying and Selling Activity at DermTech

DermTech Company Overview

DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.

Today's Range

Now: N/A

50 Day Range

MA: $0.19

$0.05

$0.42

2 Week Range

Now: N/A

Volume

3,662,300 shs

Average Volume

1,065,175 shs

Market Capitalization

$3.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.48

Has Trump Finally Gone Too Far?

From Insiders Exposed | Ad